Including Adverse Effects_Chinese Journal of Evidence-Based Medicine

Authors：

Yoon K Loke

Corresponding author：

Keywords：

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： Yoon K Loke,Deirdre Price,Andrew Herxheimer. Including Adverse Effects. Chinese Journal of Evidence-Based Medicine, 2007, 07(10): 765-767. doi: Copy

1.	Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag (Cochrane review). The Cochrane Database of Systematic Reviews 2002, Issue 2 Art. No.: CD001520. DOI: 10.1002/14651858.CD001520.
2.	Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Safety. 2005, in press.
3.	Derry S, Kong Loke Y, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Medical Research Methodology, 2001, 1: 7.
4.	Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ, 2000, 321: 1183-1187.
5.	Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet, 2000, 356: 1255-1259.
6.	Edwards JE, McQuay HJ, Moore RA, et al. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. Journal of Pain and Symptom Management, 1999, 18: 427-437.
7.	Eypasch E, Lefering R, Kum CK, et al. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ, 1995, 311: 619-620.
8.	Golder S, Duffy S, Glanville J, et al. Developing efficient search strategies to identify papers on adverse events. A: testing and precision sensitivity[abstract]. In: 12th Cochrane Colloquium 2004 Oct 2-6; Ottawa, Ontario, Canada: 75-6.
9.	Golder S, Duffy S, Glanville J, et al. Developing efficient search strategies to identify papers on adverse events. B: using statistical analysis [abstract]. In: 12th Cochrane Colloquium 2004 Oct 2-6; Ottawa, Ontario, Canada: 75.
10.	Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine, 2004, 141: 781-788.
11.	Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. Journal of the American Medical Association, 2001, 285: 437-443.
12.	Jefferson T, Demichel i V. Balancing benefits and harms in health care: observational data on harm are already included in systematic reviews. BMJ, 2003, 327: 750.
13.	Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. British Journal of Clinical Pharmacology, 2004, 57: 616-621.
14.	Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clinical Pharmacology, 2001, 1: 3.
15.	McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic reviews. BMC Medical Research Methodology, 2004, 4: 19.
16.	MacLehose H, Klaes D, Garner P. Amodiaquine: a systematic review of adverse events. Version 1, March 2003. WHO. Available at: http://www.who.int/medicines/oranization/par/edl/expcom13/expcom03add.shtml.
17.	Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. International Journal of Risk and Safety in Medicine, 2003, 16: 5-19.
18.	Olsen H, Klemetsrud T, Stokke HP, et al. Adverse drug reactions in current antihypertensive therapy: A general practice survey of 2586 patients in Norway. Blood Pressure, 1999, 8: 94-101.
19.	Wald NJ, Morris JK. Teleoanalysis: Combining data from different types of study. BMJ, 2003, 327: 616-618.
20.	Zanchetti A, Hansson L. Risk of major gastrointestinal bleeding with aspirin. Lancet, 1999, 353: 148-150.

1. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag (Cochrane review). The Cochrane Database of Systematic Reviews 2002, Issue 2 Art. No.: CD001520. DOI: 10.1002/14651858.CD001520.
2. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Safety. 2005, in press.
3. Derry S, Kong Loke Y, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Medical Research Methodology, 2001, 1: 7.
4. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ, 2000, 321: 1183-1187.
5. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet, 2000, 356: 1255-1259.
6. Edwards JE, McQuay HJ, Moore RA, et al. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. Journal of Pain and Symptom Management, 1999, 18: 427-437.
7. Eypasch E, Lefering R, Kum CK, et al. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ, 1995, 311: 619-620.
8. Golder S, Duffy S, Glanville J, et al. Developing efficient search strategies to identify papers on adverse events. A: testing and precision sensitivity[abstract]. In: 12th Cochrane Colloquium 2004 Oct 2-6; Ottawa, Ontario, Canada: 75-6.
9. Golder S, Duffy S, Glanville J, et al. Developing efficient search strategies to identify papers on adverse events. B: using statistical analysis [abstract]. In: 12th Cochrane Colloquium 2004 Oct 2-6; Ottawa, Ontario, Canada: 75.
10. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine, 2004, 141: 781-788.
11. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. Journal of the American Medical Association, 2001, 285: 437-443.
12. Jefferson T, Demichel i V. Balancing benefits and harms in health care: observational data on harm are already included in systematic reviews. BMJ, 2003, 327: 750.
13. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. British Journal of Clinical Pharmacology, 2004, 57: 616-621.
14. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clinical Pharmacology, 2001, 1: 3.
15. McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic reviews. BMC Medical Research Methodology, 2004, 4: 19.
16. MacLehose H, Klaes D, Garner P. Amodiaquine: a systematic review of adverse events. Version 1, March 2003. WHO. Available at: http://www.who.int/medicines/oranization/par/edl/expcom13/expcom03add.shtml.
17. Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. International Journal of Risk and Safety in Medicine, 2003, 16: 5-19.
18. Olsen H, Klemetsrud T, Stokke HP, et al. Adverse drug reactions in current antihypertensive therapy: A general practice survey of 2586 patients in Norway. Blood Pressure, 1999, 8: 94-101.
19. Wald NJ, Morris JK. Teleoanalysis: Combining data from different types of study. BMJ, 2003, 327: 616-618.
20. Zanchetti A, Hansson L. Risk of major gastrointestinal bleeding with aspirin. Lancet, 1999, 353: 148-150.

Chinese Journal of Evidence-Based Medicine

Including Adverse Effects

Abstract Full text Figures/Tables Video References Cited by

Format

Content